Oklahoma Startup Uses Phage Therapy to Combat Superbugs

A startup based in Stillwater, Oklahoma, is taking a novel approach to combat superbugs by utilizing phages, which are viruses that specifically target bacteria. Led by William Colton, the company, Paldara Pharmaceuticals, is working on developing a more effective delivery system for phage therapy, a method that could revolutionize the treatment of antibiotic-resistant infections.

Colton’s interest in this field began with a desire to be a marine biologist, but his path shifted towards exploring the unseen world of bacteria and their natural predators. In his small laboratory at the Meridian Technology Center, he demonstrates how phages, which are much smaller than traditional viruses, can effectively target harmful bacteria such as E. coli. “This whole plate,” he points out, indicating a petri dish, “was covered in E. coli. Our phages are specifically designed to feed on these bacteria.”

Phages represent a natural control mechanism for bacterial populations, making them a promising alternative to antibiotics. Colton explains that his approach is akin to integrating cutting-edge technology into a consumer-friendly product: “We’re like an Intel chip for space technology. We enable it to be an easier consumer experience.”

One of the advantages of phage therapy is the stability of the product. Colton notes that his phages do not require cold storage and can remain effective at room temperature for up to 10 years. “Those samples have been sitting out for more than two years,” he states, showcasing the longevity of his product.

Though still in the pre-clinical testing phase, Colton’s research has garnered attention from major institutions, including the Mayo Clinic and the OU College of Medicine. “We’re working with some of the biggest players in the market,” he asserts, highlighting the significance of these collaborations.

Colton’s motivation extends beyond scientific curiosity; he has a personal connection to the issue. He lost his grandmother due to a post-operative infection, which was resistant to antibiotics. “She just deteriorated,” he recalls. “She went septic because the antibiotics weren’t working, and she passed away.” This experience drives him to innovate in the field of phage therapy, aiming to prevent similar tragedies for others.

The initial funding for Paldara Pharmaceuticals came from a $21,000 prize he won in a business pitch competition at Oklahoma State University. At just 26 years old, Colton understands that developing this therapy will take time, but he remains committed to advancing his research.

As the battle against antibiotic-resistant infections continues, Colton’s work with phage therapy could represent a significant breakthrough in medical science. By harnessing the power of these natural bacteria-eating viruses, Paldara Pharmaceuticals aims to pave the way for safer and more effective treatments for superbug infections in the future.